Validation of the Hebrew Version of the Montreal Affective Voices.

Depression Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01512732
• Other study ID #: HebVerMAV-HMO-CTIL
• Status: Not yet recruiting
• Phase: N/A
• First received: January 15, 2012
• Last updated: January 22, 2012
• Start date: February 2012

Study information

• Verified date: January 2012
• Source: Hadassah Medical Organization
• Contact: Renana Eitan, Dr
• Phone: 972-050-4048165
• Email: renanaeitan[@]gmail.com
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health - Director General
• Study type: Observational

Clinical Trial Summary

Today, no non-verbal auditory stimuli that assess mental processing are available in Israel. The goal of this study is to make available a validated set of auditory stimuli in Israel. We created a computerized Hebrew version of the Montreal Affective Voices (MAV). The MAV is a novel tool for assessing mental processing. The MAV consists of 90 nonverbal affect bursts corresponding to nine different emotions (such as anger, fear, happiness etc.) recorded by ten different actors. The uniqueness of these affective bursts is that they do not contain verbal context, but rather express affective moods using the vowel /a/ (as in "apple"). In this study, the investigators will verify the new Hebrew version of MAV in healthy control groups. Next, the investigators will compare the mental processing ability in young vs. old population, using the MAV test. In addition, the investigators will assess mental processing in two pathologic study groups (Parkinson's disease, major depressive disorder) using the MAV test. The investigators intend to use the MAV tool in future research in Parkinson's disease and depression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy group

• Parkinson's disease

• Major depressive disorder

• All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26.

Exclusion Criteria:

• Non-competent or unable to give written informed consent

Study Design

N/A

Related Conditions & MeSH terms

• Depression
• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
Israel	Hadassah Medical Organization,	Jerusalem,

Sponsors (1)

Lead Sponsor	Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups.		12 months	No